tinea%20capitis
TINEA CAPITIS
Tinea capitis  is a contagious dermatophytosis affecting the hair shaft and follicles of the scalp, eyebrows and eyelashes.
It is most common in the crowded areas as infection originates from contact with a pet or an infected person and asymptomatic carriage persists indefinitely.
It primarily affects children 3-7 years of age.
The causative agents are the genus Trichophyton and Microsporum.
Cardinal clinical feature is the combination of inflammation with hair breakage and loss.

Diagnosis

  • All specimens obtained (scalp scrapings, hair follicles) should undergo microscopy & culture, w/ causative organism identified

Laboratory Tests

Microscopy

  • Provides the most rapid means of diagnosis but may not always be positive in affected patients
  • Scalp scales &/or hair are mounted in 10-30% potassium hydroxide (KOH) solution, gently heated & viewed under light or flourescence microscope
  • Positive results reveal hairs and scales invaded by spores &/or hyphae

Causative Agents

  • Large-spored endothrix pattern chains of large spores within hair (Trichophyton tonsurans, T violaceum)
  • Large-spored ectothrix (T verrucosum, T mentagrophytes)
  • Small-spored ectothrix randomly arranged in masses inside & on the surface of the hair shaft (Microsporum canis, M audouinii)

Dermoscopy (Trichoscopy)

  • A noninvasive in vivo imaging technique that may aid in the diagnosis of Tinea capitis, especially in patients w/ black dot pattern

Culture

  • Allows accurate identification of organism but results may take up to 4 weeks
  • Use of Sabouraud agar w/ 1 or more plates w/ cycloheximide is recommended
  • Results may be positive even when microscopy is negative
  • Necessary in hair fungal infections to identify the source of infection & verify the infecting species

Wood’s Light Exam

  • Useful for certain ectothrix infections (eg M canis, M audouini, M rifalieri)
  • If present, will cause hair to fluoresce bright green
  • T tonsurans which causes most Tinea capitis does not fluoresce
Editor's Recommendations
Most Read Articles
Pearl Toh, 5 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.